ClinicalTrials.gg
CompletedNCT03934450Updated May 14, 2019

Metabolism and Pharmacokinetics of Primaquine Enantiomers in Human Volunteers Receiving a Seven Day Dose Regimen

A Phase 1 interventional study of RPQ and SPQ in Malaria and Glucose 6 Phosphate Dehydrogenase Deficiency, sponsored by University of Mississippi, Oxford. Completed at 1 site in United States. Open to participants aged 18 Years to 65 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2019-05-14.

Sponsored by University of Mississippi, Oxford · Phase 1, Interventional, and Basic science

How we know

From the registry’s dates

  • Primary completion was May 2019, 7 years 6 months ago, and no results have been posted to the registry.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
36
Allocation
Non-randomized
Ages
18 Years to 65 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 105 studies in Malaria with a site in United States — 9 open to participants now, 10 under way, none of them phase 3. Malaria · United States.

Enrollment
57th of 89
36 · median 45
Started
2018
with 6 others
Phase 1
62 of 105
1 open now
Registered
80th of 105
by date
Lead sponsor
3 of 105
University of Mississippi, Oxford

Among the 105 studies in Malaria with a site in United States, this one is the 57th largest by enrollment of the 89 interventional ones that give a count, is one of 7 that started in 2018, is one of 62 in phase 1, and was the 80th registered.

Malaria

1,187 studies on the registry are indexed under Malaria; 80 are open to participants now.

Browse Malaria studies →

Open to participants now

9 of the 105 studies in Malaria with a site in United States are open now. Recruiting first, the newest first:

4 more — sign in →

All 9 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 51 Malaria studies recruiting now, 15 (29%) set no upper age limit and 33 (65%) stop at 75 or younger; 37 take children under 18; 31 take healthy volunteers.

This study: 18 Years to 65 Years · all sexes · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 105 studies in Malaria with a site in United States, or all of them as a file.
02

Study summary

To investigate the comparative tolerability, metabolism and pharmacokinetics of individual enantiomers of PQ in healthy human volunteers, receiving study drug over the course of 7 days.

Read the detailed description

The primary objective of this project is to investigate the comparative tolerability, metabolism and pharmacokinetics of individual enantiomers of PQ in healthy human volunteers. Based on the results of this study, if one enantiomer seems to show a better safety profile (in terms of hematological effects), an analogous study will be carried out in G6PD deficient individuals (under a separate protocol). The studies are primarily aimed at understanding the tolerability and safety of the enantiomers in G6PD deficiency. If one shows a better safety profile, ultimately the evaluation of its efficacy will be required.

03

Conditions studied

  • Malaria
  • Glucose 6 Phosphate Dehydrogenase Deficiency

Keywords

  • Hemolysis
  • Primaquine
  • Pharmacokinetics
04

Who can participate

Ages eligible
18 Years to 65 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Normal, healthy adults aged 18 to 65 years

Exclusion criteria

Exclusion Criteria:

  • Known history of liver, kidney or hematological disease
  • Known history of cardiac disease, Non Sinus Rhythm arrhythmia or
  • disorders
  • Report of an active infection
  • Evidence of G6PD deficiency
  • Participant is pregnant or breast-feeding, or is expecting to conceive during the study.
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

QT and QTc

On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.

The study may name a correction formula and a limit in milliseconds, often around 450–480.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

05

Study design

Phase
Phase 1
Primary purpose
Basic science
Allocation
Non-randomized
Intervention model
Crossover assignment
Masking
Single (Participant)
Enrollment
36 participants (actual)

Study arms

  • Experimental
    RPQ (-) enantiomer

    Cohort 1 will receive 15 mg of RPQ (3A) every day for 7 days Cohort 2 will receive 22.5 mg of RPQ (3A) every day for 7 days

    Drug: RPQ

  • Experimental
    SPQ (+) enantiomer

    Cohort 1 will receive 15 mg of SPQ (2A) every day for 7 days Cohort 2 will receive 22.5 mg of SPQ (2A) every day for 7 days

    Drug: SPQ

  • Active comparator
    Primaquine Phosphate

    Cohort 1 will receive 30 mg of RSPQ (1A) every day for 7 days Cohort 2 will receive 45 mg of RSPQ (1A) every day for 7 days

    Drug: Primaquine Phosphate

  • Placebo comparator
    Placebo

    Cohort 1 will receive placebo (4A) capsules everyday for seven days Cohort 2 will receive placebo (4A) capsules everyday for seven days

    Drug: Placebo

Interventions

  • DrugRPQ

    The study will compare the individual enantiomers of primaquine - R- (-)-PQ, S-(+)-PQ, and Placebo along with the racemic version.

    Also known as: R-(-) Enantiomer of Primaquine Phosphate

  • DrugSPQ

    The study will compare the individual enantiomers of primaquine - R- (-)-PQ, S-(+)-PQ, and Placebo along with the racemic version.

    Also known as: S-(+) Enantiomer of Primaquine Phosphate

  • DrugPrimaquineStudies of PrimaquinePrimaquine pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record.

    The study will compare the individual enantiomers of primaquine - R- (-)-PQ, S-(+)-PQ, and Placebo along with the racemic version.

    Also known as: Racemic Primaquine

  • DrugPlacebo

    The study will compare the individual enantiomers of primaquine - R- (-)-PQ, S-(+)-PQ, and Placebo along with the racemic version.

06

What researchers measure

Primary outcomes

  1. Change in Methemoglobin concentration in blood from baseline

    Change in Methemoglobin concentration in blood from baseline (% hemoglobin)

    Time frame: Days 0, 3, 5, 7

Secondary outcomes

  1. Primaquine Plasma concentration, ng/mL

    Plasma concentrations of parent drug

    Time frame: Days 0, 3, 5, 7

  2. Carboxy- Primaquine Plasma concentration, ng/mL

    Plasma concentrations of carboxy-primaquine metabolite

    Time frame: Days 0, 3, 5, 7

  3. Primaquine N-carbamoyl-glucuronide Plasma concentration, ng/mL

    Plasma concentrations of Primaquine N-carbamoyl-glucuronide metabolite

    Time frame: Days 0, 3, 5, 7

  4. Primaquine Orthoquinone Plasma concentration, ng/mL

    Plasma concentrations of Primaquine Orthoquinone metabolite

    Time frame: Days 0, 3, 5, 7

  5. Change in Hematocrit (%) Compared to baseline

    Change in Hematocrit (%) Compared to baseline

    Time frame: Days 0, 3, 5, 7

  6. Change in Hemoglobin (g/dL) Compared to baseline

    Change in Hemoglobin (g/dL) Compared to baseline

    Time frame: Days 0, 3, 5, 7

  7. Change in AST (U/L) Compared to baseline

    Change in Aspartate aminotransferase (U/L) Compared to baseline; used to monitor liver function

    Time frame: Days 0, 3, 5, 7

  8. Change in ALT (U/L) Compared to baseline

    Change in Alanine aminotransferase (U/L) Compared to baseline; used to monitor liver function

    Time frame: Days 0, 3, 5, 7

  9. Change in Total Bilirubin (mg/dL) Compared to baseline

    Change in Total Bilirubin (mg/dL) Compared to baseline; used to monitor liver function and red cell integrity

    Time frame: Days 0, 3, 5, 7

07

Study locations

1 site
  • University of Mississippi
    University, Mississippi 38677, United States
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Aug 2018 to primary completion in May 2019, 8 months.

Of 64 non-industry phase 1 interventional studies under Malaria, half reached primary completion within 13 months of starting (the median), counting those still running; a quarter within 7 and three quarters within 24. This study's 8 months is below that.

Counting every sponsor, half of 93 studies reached it within 13 months; a quarter within 7 and three quarters within 20.

How these figures are worked out, and which studies are left out of them.

Registered
May 14, 2018
First posted
May 1, 2019
StartActual
Aug 17, 2018
Primary completionActual
May 1, 2019
CompletionActual
May 1, 2019
Last update
May 14, 2019
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on May 14, 2019, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT03934450
Lead sponsor
University of Mississippi, Oxford
Responsible party
Sponsor
First posted
May 1, 2019
Start date
Aug 17, 2018
Primary completion
May 1, 2019
Completion
May 1, 2019
Last update
May 14, 2019

Study contacts

Larry Walker, Phd
principal investigator · University of Mississippi Medical Center

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in May 2019. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion